EPHA1 and glioma: The distinctive biological features of the EPH/ephrin signaling pathway present potential therapeutic targets for pediatric glioma treatments, especially those for high-grade tumors, which need more targeted approaches due to their biologic heterogeneity and poor prognosis with the current standard therapies (surgery, irradiation, and chemotherapy with temozolomide, either combined or not with targeted therapies in the field of pediatric clinical trials) [93].